MedTrace Logo

Dietary Interventions in Asthma Treatment: Sprouts Study

NCT01183923 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2019-06-04

Study results available
· View outcomes & findings →

Summary

Sulforaphane (SFN) is a naturally occurring isothiocyanate that is a potent inducer of Phase II enzymes which play a critical role in preventing oxidative stress (via activation of Nrf2). Broccoli sprouts (BS) contain the richest source of SFN.

The main objectives of this study are to test the effect of broccoli sprouts (BS) on biomarkers of oxidative stress (OS), inflammation, basophil activation, and clinical outcomes in mouse allergen-induced asthma by (1) determining if BS improves lung function and airways symptom responses in mouse-sensitized adults with asthma undergoing environmental mouse allergen challenge (EMAC), (2) examining the effect of BS on OS, inflammation, and basophil activation, and (3) examining the effect of BS on changes in OS, inflammation, and basophil activation after EMAC.

Conditions

Interventions

OTHER

Broccoli Sprouts

Broccoli Sprouts will be eaten daily in a sandwich form during the intervention period for broccoli sprouts.

OTHER

Alfalfa Sprouts

Alfalfa sprouts will be eaten daily in a sandwich form during the intervention period for alfalfa sprouts.

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Institute of Environmental Health Sciences (NIEHS)

    collaborator NIH

  • Massachusetts General Hospital

    collaborator OTHER

  • Johns Hopkins University

    lead OTHER

Principal Investigators

  • Elizabeth C Matsui, MD MHS · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-02-06
Completion
2012-02-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01183923 on ClinicalTrials.gov